Clinical Study Results
Research Sponsor: AstraZeneca AB
Drugs Studied: RDEA3170, febuxostat, and dapagliflozin
Study Title: A study to learn how treatment with RDEA3170, febuxostat, and
dapagliflozin works and how safe it is in people with high levels of
uric acid in their blood.
Thank you!
Thank you for taking part in the clinical study for the study drugs RDEA3170, febuxostat,
and dapagliflozin. You and all of the participants helped researchers learn more about
using these study drugs together to help people with high levels of uric acid in their blood.
AstraZeneca AB sponsored this study and thinks it is important to share the results of the
study with you and the public. An independent, non-profit organization called CISCRP
helped prepare this summary of the study results for you. We hope it helps you understand
and feel proud of your important role in medical research.
If you participated in the study and have questions about the results, please speak with
the doctor or staff at your study site.
What is happening with the study now?
You and the other participants were in the study for up to about 10 weeks. The study
started in October 2017 and ended in July 2018. The study included 36 participants in the
United States.
The sponsor reviewed the data collected when the study ended and created a report of
the results. This is a summary of that report.
1